 STOCKHOLM, April 6, 2021 PRNewswire -- Medivir AB Nasdaq Stockholm: MVIR today announces that the Annual Report for 2020 now is available at the companys website: In the spring of 2020, Medivir was able to present promising data from the phase Ia study and shortly thereafter initiate the phase Ib study with MIV-818, our proprietary and wholly owned candidate drug for liver cancer. 